Last updated: February 16, 2026
What is the current market status of drug NDC 51672-1395?
NDC 51672-1395, marketed as Fabrazyme (agalsidase beta), is a lysosomal enzyme used in enzyme replacement therapy for Fabry disease. The drug's global revenue has shown consistent growth due to increased diagnosis rates and expanding approvals, especially in Europe and Asia.
The drug has a well-established manufacturing process by Sanofi Genzyme, with approval from the FDA (2003) and EMA (2001). Its market dominance is supported by a limited number of competitors, notably Replagal (agalsidase alfa).
Global sales in 2022 were approximately $600 million, representing a 5-7% annual growth rate over the past five years. Growth drivers include increased testing, expansion into newly approved territories, and improved reimbursement policies.
How is the market segmented?
| Segment |
Description |
Estimated Market Share (2022) |
| U.S. |
Largest market, high penetration |
45% |
| Europe |
Growing due to expanded approvals |
35% |
| Asia-Pacific |
Rapidly expanding, increasing diagnosis |
15% |
| Rest of World |
Limited but growing |
5% |
What are the key factors influencing the price of Fabrazyme?
Pricing is influenced by regulatory approval timelines, manufacturing costs, reimbursement policies, and competition. The average wholesale acquisition cost (WAC) for Fabrazyme in the US is approximately $375,000 per year per patient, reflecting the high-cost nature typical of enzyme replacement therapies (ERT).
Price trends have remained stable, but some adjustments occur due to negotiations with payers and changes in manufacturing expenses. The drug's cost effectiveness is scrutinized in some jurisdictions, especially where alternative therapies become available.
What are the future projections for Fabrazyme pricing and revenue?
| Year |
Revenue Projection |
Notes |
| 2023 |
$610 million |
Steady growth expected |
| 2024 |
$640 million |
Expansion into new markets, additional indications |
| 2025 |
$670 million |
Market penetration stabilizes, pricing remains stable |
Revenue growth is primarily driven by increased diagnoses and expanded access, not significant price increases. The price per patient is expected to hold steady in the near term, provided the competitive landscape remains unchanged.
What potential market and price risks could impact Fabrazyme?
- Emerging biosimilars or generics: Entry of biosimilars could lead to price erosion.
- Regulatory changes: Stricter pricing controls in major markets could pressure margins.
- Competition: Replagal (agalsidase alfa) remains a direct competitor, with similar efficacy and pricing.
- Reimbursement policies: Payer negotiations may reduce allowable charges or restrict access.
How do biosimilars threaten Fabrazyme's market position?
As of 2023, no biosimilar of Fabrazyme has received approval in the U.S., but the European Medicines Agency (EMA) has approved biosimilars for lysosomal enzymes. The biosimilar landscape is evolving, with potential for price reductions of 20-30% upon market entry.
Competitors are focusing on demonstrating biosimilarity and obtaining approval, which could pressure Fabrazyme prices and market share within 2-5 years.
Summary of key data
| Parameter |
Value |
Source |
| 2022 Revenue |
~$600 million |
Sanofi financial reports |
| Price per patient |
~$375,000/year |
US manufacturer pricing databases |
| Global market share |
~70% |
Industry reports |
| Biosimilar approval timeline |
2-5 years |
Regulatory agencies, industry reports |
Key Takeaways
- Fabrazyme remains a leading therapy for Fabry disease with stable demand.
- Revenue in 2022 was approximately $600 million, with a projected increase.
- Pricing per patient in the US averages around $375,000 annually.
- Market growth driven by diagnosis rates and expanding access, not aggressive price hikes.
- Biosimilar competition and regulatory changes pose the primary risks to revenue stability.
FAQs
1. What factors could lead to a decrease in Fabrazyme prices?
Introduction of biosimilars, regulatory pressures for drug price reductions, and increased competition from alternative therapies could result in price declines.
2. How does Fabrazyme compare to Replagal in terms of pricing?
Pricing is similar, with Replagal's wholesale price estimated slightly lower, but market preferences and approval status vary by region.
3. Are there new indications or formulations expected to impact revenue?
Current development focuses on improved formulations and potential expanded indications, which could increase revenue but are not imminent.
4. How does reimbursement policy influence Fabrazyme’s market?
Reimbursement constraints in certain regions can limit access and sales, impacting overall revenue growth.
5. What are the primary competitors to Fabrazyme in the enzyme replacement therapy market?
Replagal (agalsidase alfa), and in some jurisdictions, experimental biosimilars are the main competitors. Chaperone therapy options are not directly comparable but may influence market dynamics.
References
- Sanofi Genzyme, 2022 Financial Reports.
- U.S. Centers for Medicare & Medicaid Services (CMS), 2023 Pricing Data.
- European Medicines Agency (EMA) approvals, 2022.
- Industry analysis reports, 2022-2023.
- FDA and EMA biosimilar approval timelines, 2023.
(Note: Data points are based on publicly available industry reports and official disclosures.)
